Press releases

Release issued 15th May 2006

York, UK, 15 May 2006—India is an increasingly attractive destination for R&D activities in the pharmaceutical and biotechnology industry. Being an emerging market, companies face a number of unique hurdles before entering this lucrative region.

Bridgehead International's new report 'India: Pharmaceutical and biotechnology opportunities' (http://pharmalicensing.com/reports/) provides an overview of the Indian pharma and biotech market, and answers the following key questions:

* Who are the key players in the Indian pharmaceutical market?

* How has the Indian regulatory environment changed?

* What R&D collaborative opportunities are available?

* How can companies engage with India for collaboration?

* What are the leading R&D companies in India doing in collaborative R&D?

Readers will gain an analysis of the regulatory environment, insights into collaborative opportunities and detailed information on the key companies, clusters and government initiatives.

This report is a valuable resource for use by all those developing company strategy and direction in this key emerging market.

'India: Pharmaceutical and biotechnology opportunities' is based on the December 2004 report 'India: The emerging R&D collaborative opportunity'. The new report includes additional sections on the Indian Patents Act 2005, the Indian pharmaceutical policy, an overview of Department of Biotechnology initiatives, including details of biotechnology parks, and an all new set of profiles on life science research institutes.

The profiles section of 'India: Pharmaceutical and biotechnology opportunities' contains updated profiles and contact details on key companies.

For more information on 'India: Pharmaceutical and biotechnology opportunities' or other reports, go to http://pharmalicensing.com/reports/, or contact the reports team on tel: +44 1904 520460 or email: keyreports@bridgehead.com.

Pharmalicensing (http://pharmalicensing.com), based in York, UK, is the world's number one partnering resource for the biopharmaceutical industry. Pharmalicensing provides pharmaceutical companies with a wide-ranging forum to exchange partnering wants and needs with a global audience.

Bridgehead International is a leading biopharmaceutical consultancy group, offering a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain, through three divisions: Bridgehead Consulting; Healthcare Education Services; and Pharmalicensing.

Contact: Suzanne Elvidge, Head of Publishing (suzanne.elvidge@bridgehead.com; Tel +44 1904 520464)

(20th October 2011) Bridgehead International Appoints Expert in Global Pricing and Market Access for Oncology Products

(20th October 2011) Bridgehead International announces publication by The Personalized Medicine Coalition (PMC) of a white paper entitled “Advancing Access to Personalized Medicine: A Comparative Assessment

(13th September 2011) Bridgehead International Appoints Marcus Deans as Principal Consultant

(1st August 2011) Bridgehead International Announces US West Coast Expansion

(14th June 2011) Bridgehead International appoints Nigel Seear as Vice President, Europe